Ariceum Therapeutics’ targeted radiopharmaceutical 177Lu-satoreotide exhibits promising clinical response and good tolerability profile in patients with advanced neuroendocrine tumours
- 95% of patients (36 of 38) treated with Ariceum’s radiopharmaceutical satoreotide achieved disease control in Phase I/II trial
- That included 21% of patients (8 of 38) who experienced tumour reduction
- The study, just published in the European Journal of Nuclear Medicine and Molecular Imaging, concluded the treatment “has an acceptable safety profile with a promising clinical response” in SSTR2+ NET patients
Berlin, Germany, 28th September 2023 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, is pleased to announce the publication of positive results from a Phase I/II trial of its radiopharmaceutical 177Lu-satoreotide tetraxetan (satoreotide) in patients with previously treated, progressive neuroendocrine tumours (NETs), in the European Journal of Nuclear Medicine and Molecular Imaging.
